Management of Fatty Liver Disease

Primary Treatment: Lifestyle Modification

The American Association for the Study of Liver Diseases recommends achieving 7-10% weight loss to improve steatohepatitis and achieve fibrosis regression 1, 2
A weight loss of 5% improves steatosis alone, while 7-10% weight loss is required for fibrosis regression 2, 3
Weight loss must be gradual at 500-1000g per week maximum, as rapid weight loss worsens liver disease 2
The European Association for the Study of the Liver suggests implementing a Mediterranean diet pattern featuring daily vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil, which reduces liver fat even without weight loss 1, 3, 4
Creating a 500-1000 kcal/day deficit is recommended, typically 1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men 2, 3
Eliminating fructose-containing beverages and processed foods is advised, as well as replacing saturated fats with monounsaturated and polyunsaturated fats, especially omega-3 fatty acids 1, 2, 4

The American College of Sports Medicine recommends prescribing 150-300 minutes of moderate-intensity aerobic exercise per week or 75-150 minutes of vigorous-intensity exercise 1, 3, 4
Both aerobic exercise and resistance training effectively reduce liver fat, with vigorous exercise carrying greater benefit than moderate exercise for NASH and fibrosis 1

The American Association for the Study of Liver Diseases recommends statins for dyslipidemia management in all NAFLD patients, as they reduce HCC risk by 37% 2, 3
For diabetes, considering GLP-1 agonists can be effective for NASH recovery, while avoiding sulfonylureas and insulin is recommended as they may increase HCC risk 2, 3

The American Society for Metabolic and Bariatric Surgery suggests considering bariatric surgery for patients with severe obesity who meet national eligibility criteria, as it resolves NASH in 85% of patients at 1 year post-surgery and improves steatosis, steatohepatitis, and fibrosis 3

The European Association for the Study of the Liver states that cardiovascular disease is the main driver of morbidity and mortality in NAFLD patients before cirrhosis develops, emphasizing the need to address all metabolic risk factors aggressively 2, 3, 4
Assessing lipid profile, fasting glucose/HbA1c, waist circumference, and BMI is crucial, as well as using non-invasive tests to identify patients at risk for advanced fibrosis 1, 2, 3, 4